Insider Purchases: Inside the Buy

Tag: 10% owner buying

Illustration showing advanced cancer diagnostics and DNA science balanced against financial risk, representing Mainz Biomed’s promising technology and high-risk biotech investment profile.

Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances

Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.

Read entire article

Tags: 10% owner buying, Biotech Stocks, buy or sell MYNZ, Colorectal Cancer, Early Cancer Detection, featured-insiders, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Going Concern, High Risk High Reward, hub-insiders, hub-overseas, Insider Buying, Mainz Biomed, Microcap Biotech, MYNZ, Pancreatic Cancer, risks buying mynz, Speculative Stocks, why buy mynz